Friday, January 05, 2007 11:38:31 PM
Apparently, some time later Insmed put forth the defense of inequitable conduct in an attempt to have the '151 declared unenforceable. Exactly when that occurred I do not know. The first I saw of it was in a court document filed in October, and it appeared the judge took a dim view of having it put on the table at such a late date. That leads me to believe the IC may have been made an isssue by Insmed as a fallback position just prior to trial, but I certainly do not know that for sure. However, if that was the case, it might explain why the judge decided to let the case go to the jury before any IC hearing. It may have been that the only question before the court at that time was the one on prior art, and she had already ruled on that. (The Insmed brief on IC wasn't even filed until AFTER the case had gone to the jury.) If that indeed was the case and I was the judge, I would be more than a little pissed for having been put in that position.
I would think though it may be a "no harm, no foul" situation in that IF the judge grants the IC motion ... which I personally doubt ... she can set aside the infringement issues with the '151 patent and adjust any royalties accordingly. If, on the other hand, she denies the IC motion Insmed now at least has put all they have into the record for an appeal.
I think we have to keep two things in mind during the next few weeks. One is that we do not know all that goes on in the court. The other is that the court (any court) does not rule on any question that does not come before it. In theory, the judge may agree with us but she can only rule on what has been brought before the court by either the plaintiffs or defendants. At the Markman Hearing Insmed had only contended prior art (which the judge rejected). The IC motion apparently came later.
Recent INSM News
- New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results • PR Newswire (US) • 10/08/2024 08:05:00 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 10/04/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 08:47:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 08:46:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/13/2024 08:28:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 11:49:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/10/2024 08:14:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 08:06:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/06/2024 08:19:01 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 09/06/2024 12:00:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 09/03/2024 09:22:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:10:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2024 07:57:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:28:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:26:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 08:05:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 08:01:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 09:30:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:00:26 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 11:00:05 AM
- Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update • PR Newswire (US) • 08/08/2024 11:00:00 AM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 08/02/2024 12:00:00 PM
- Insmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024 • PR Newswire (US) • 07/29/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2024 09:19:37 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 07/05/2024 12:00:00 PM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM